Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**K-252a** is an indolocarbazole-based alkaloid and a staurosporine analog isolated from Nocardiopsis and Actinomadura species. It is a potent, broad-spectrum inhibitor of protein kinases, including protein kinase C (PKC), protein kinase A (PKA), protein kinase G (PKG), calcium/calmodulin-dependent kinase II (CaMKII), phosphorylase kinase, tropomyosin receptor kinases (Trk/NTRK family), myosin light-chain kinase, mixed-lineage protein kinase 3, FLT3 receptor tyrosine-protein kinase, and actin-regulating kinases. Its mechanism of action involves competitive inhibition at the ATP binding site of these kinases. At nanomolar concentrations it potently inhibits Trk receptors and blocks nerve growth factor signaling in neuronal cells. Preclinical research has explored its use as an antimicrobial agent and as a potential treatment for psoriasis; it also exhibits neuroprotective effects at low concentrations but can induce apoptosis by inhibiting cell cycle regulators such as Cdc2 and Cdc25[1][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on K-252a.